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Background: The purpose of this study is to evaluate how wetting of Collatamp (a gentamicin-containing
collagen implant [GCCI]) impacts on the gentamicin content of the implant and whether this affects its
potential antibacterial efﬁcacy.
Methods: GCCI (Collatamp, EUSA Pharma [Europe], Oxford, United Kingdom) containing 130 mg
gentamicin and 280 mg collagen (10 cm  10 cm) were immersed in 300 mL normal saline for up to 6h.
At set times after immersion the GCCI were removed, the saline diluted in normal human serum and the
gentamicin content assayed by a validated immunoassay (Cedia, Microgenics Ltd, UK) to provide an
estimate of the loss from each implant. The mean concentration data were then ﬁtted to an exponential
decay model (WinNonLin, Pharsight, US).
Results: After a very short immersion period there was signiﬁcant loss of gentamicin from the implants
with a mean loss of 6.7% at 2 s, increasing to 40.5% at 1 min and essentially total loss by 6 h of immersion.
Loss of gentamicin followed a complex elution proﬁle, with elution half-lives ranging from 50 s on initial
immersion to 99 min late in the elution period.
Conclusion: This study provides clear evidence that even a short period of dipping of Collatamp implants,
and probably other GCCI, before insertion into the patient results in a signiﬁcant loss of gentamicin which
may be of clinical signiﬁcance unless the period of soaking is very short. We therefore recommend that
wetting of these implants before insertion is not undertaken.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gentamicin-containing collagen implants (GCCI), are commonly
used in surgical procedures where there is either a high risk of
wound infection1 or where any post-operative infection is associ-
ated with signiﬁcant morbidity and mortality. GCCI are inserted at
wound closure and deliver high local gentamicin concentrations
without signiﬁcant systemic exposure. Although the primary
function of GCCI is to provide haemostasis, a number of studies
have shown signiﬁcant reductions in the incidence of surgical site
infection associated with their use.2e5 However, two recent
studies6,7 have contradicted the positive beneﬁts seen in earlier
studies and these, counter intuitive ﬁndings have lead others to
question the clinical utility of GCCI.8 There have been anecdotal
reports of surgeons wetting GCCI prior to insertion to facilitate
handling and this approach was used in the two recent
studies.6,7,9,10 Therefore the purpose of this paper is to evaluate how
wetting impacts on the gentamicin content of GCCI and whether
this affects their potential antibacterial efﬁcacy.fax: þ44 (0)117 3238332.
. Lovering).
ciates Ltd. Published by Elsevier Lt2. Methods
GCCI (Collatamp, EUSA Pharma [Europe], Oxford, United Kingdom) containing
130 mg gentamicin and 280 mg collagen (10 cm  10 cm) were immersed in
300 mL normal saline and gently agitated. In early experiments implants were
immersed for up to 1 min, to replicate the conditions likely to be encountered in
clinical practice, while in later experiments the implants were immersed for up to
6 h to provide a better understanding of the gentamicin elution proﬁle of the
implants. At set times after immersion the implants were removed, the saline
diluted in normal human serum and the gentamicin present assayed by a validated
immunoassay (Cedia, Microgenics Ltd, UK) to provide an estimate of the loss from
each implant. Five replicates using whole implants were used for early time points
and in the later ones three replicates with half implants were used. The mean
concentration data were then ﬁtted to an exponential decay model (WinNonLin,
Pharsight, US).3. Results
On immersion in the saline solution the GCCI (Collatamp)
rapidly took up ﬂuid to become ﬂaccid and difﬁcult to handle.
The concentrations of gentamicin base found in the saline solu-
tion were corrected for the saline volume and expressed as the
amount of gentamicin eluted from the implant in mg. This was
then expressed as a percentage loss relative to the nominald. All rights reserved.
Table 1
Loss of gentamicin from GCCI (Collatamp) on soaking in normal saline.
Elution time Sponge Replicates Gentamicin loss (%)a
Mean SD 95% CI
2 s Whole 5 6.7 0.30 6.5e7.0
5 s Whole 5 10.5 1.03 9.6e11.4
10 s Whole 5 15.3 0.63 14.8e15.9
30 s Whole 5 29.3 1.66 27.8e30.8
1 min Whole 5 40.5 3.25 37.7e43.4
2 min Half 3 50.2 7.86 41.3e59.1
5 min Half 3 62.1 10.24 50.5e73.6
10 min Half 3 69.5 7.74 60.7e78.2
30 min Half 3 74.9 7.74 66.1e83.6
60 min Half 3 79.7 6.22 72.7e86.8
180 min Half 3 92.6 3.79 88.3e96.9
360 min Half 3 102.7 1.15 101.4e104.0
a Loss expressed relative to the stated content of 130 mg gentamicin per sponge.
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Fig. 1. The elution proﬁle of gentamicin from GCCI (Collatamp) on soaking in normal
saline.
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ﬁgures are shown in Table 1. After a very short immersion period
there was signiﬁcant loss of gentamicin from the implants with
a mean loss of 6.7% at 2 s, increasing to 40.5% at 1 min and
essentially total loss by 6 h of immersion (Table 1). Loss of
gentamicin followed a complex elution proﬁle, with elution half-
lives ranging from 50 s on initial immersion to 99 min late in the
elution period (Fig. 1).4. Discussion
After relatively short periods of immersion in saline, substantial
losses of gentamicin were observed from the individual GCCI,
(Collatamp)which ranged from6.7% loss at 2 s to a 40.5% loss at 60 s
of immersion. Considering the relatively short immersion timings
and the difﬁculties of completely wetting the implant at the shorter
time periods, little variability in loss was seen between the ﬁve
replicates studied at each time point. The loss of 40.5% of the
gentamicin present in the implants after 60 s immersion in saline
suggests that a major proportion of the gentamicin is only weakly
associated with the implant, although there is evidence that some
of the gentamicin is more tightly bound to the implant as the rate of
loss was lower later in the elution proﬁle.
Considering the results found in this study in the context of the
two recent randomised controlled trials, it would be expected that
there would be a loss of gentamicin from the implants prior to
insertion into the patient due to the pre-soaking. Although this loss
of gentamicin is unlikely to have been of clinical relevance had
a very short period of pre-soaking been used, as suggested by the
authors,11 it is impossible to know how long implants were soaked
in practice. It is therefore not possible to exclude the possibility that
the pre-soaking procedure used in these studies may have
compromised the antimicrobial activity of the implants.
In conclusion, this study provides clear evidence that even
a short period of pre-soaking of Collatamp implants, and probably
other GCCI, before insertion into the patient results in a signiﬁ-
cant loss of gentamicin which may be of clinical signiﬁcance
unless the period of soaking is very short. Whether wetting the
implants also affects the in vivo gentamicin elution characteristics
was not studied, but the possibility exists that it may. Clearly,
soaking the implants before use might be expected to impact on
their utility as haemostats, but it is also quite possible that pre-
soaking may impact on the gentamicin release proﬁle of the
implants to cause premature depletion of the active compound in
addition to that lost during the pre-soaking period. We therefore
recommend that wetting of these implants before insertion is not
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